<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03363321</url>
  </required_header>
  <id_info>
    <org_study_id>B7841003</org_study_id>
    <secondary_id>2017-001255-31</secondary_id>
    <nct_id>NCT03363321</nct_id>
  </id_info>
  <brief_title>PF-06741086 Long-term Treatment in Severe Hemophilia</brief_title>
  <official_title>A Multicenter, Open-label Study To Evaluate The Long-term Safety, Tolerability And Efficacy Of Subcutaneous Or Intravenous Pf-06741086 In Subjects With Severe Hemophilia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the safety, tolerability and efficacy of long-term
      treatment with PF-06741086 in subjects with severe hemophilia who participated in the 3-month
      Phase 1b/2 B7841002 study. Additionally, de novo subjects will be recruited into this study.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 31, 2018</start_date>
  <completion_date type="Anticipated">August 22, 2019</completion_date>
  <primary_completion_date type="Anticipated">August 22, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency, severity and causal relationship of treatment emergent adverse events (TEAEs) and withdrawals due to TEAEs</measure>
    <time_frame>Day 1 up to Day 197</time_frame>
    <description>Treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with laboratory abnormalities</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Following parameters were analyzed for laboratory examination: hematology, serum chemistry, and urinalysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with changes from baseline in vital signs</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Following parameters were analyzed for vital sign examination: blood pressure, pulse rate, temperature, respiration rate.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of subjects with change from baseline in electrocardiogram (ECG) parameters</measure>
    <time_frame>Day 1 to Day 29</time_frame>
    <description>Following parameters were analyzed for ECG examinations: QT interval (QTc), QTcF interval (Fridericia's Correction), QRS complex, PR interval, and RR interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subjects with injection site reactions</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Following parameters were analyzed for injection site reaction examinations: induration, erythema, edema, rash, pruritus.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of subejct with infusion site reactions</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Following parameters were analyzed for infusion site reactions: induration, erythema, edema, rash, pruritus.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of bleeding episodes</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Bleeding episodes requiring treatment with factor replacement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of treatments for breakthrough bleeding episodes</measure>
    <time_frame>Day 1 to Day 197</time_frame>
    <description>Treatments with factor replacement.</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Hemophilia A or B</condition>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 5)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>PF-06741086 (Cohort 6)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PF-06741086</intervention_name>
    <description>PF-06741086 subcutaneous injection</description>
    <arm_group_label>PF-06741086 (Cohort 1)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 2)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 3)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 4)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 5)</arm_group_label>
    <arm_group_label>PF-06741086 (Cohort 6)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Severe hemophilia A or B (Factor VIII or Factor IX activity â‰¤ 1%)

          -  Episodic (on-demand) treatment regimen prior to screening

          -  At least 6 acute bleeding episodes during the 6-month period prior to screening

        Exclusion Criteria:

          -  Known coronary artery, thrombotic, or ischemic disease

          -  Detectable or documented history of inhibitors against Factor VIII or Factor IX during
             the 12-month period prior to screening

          -  Concomitant treatment with rFVIIa or activated prothrombin complex concentrate
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
    <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
  </overall_contact>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7841003&amp;StudyName=A+Multicenter%2C+Open-label+Study+To+Evaluate+The+Long-term+Safety%2C+Tolerability+And+Efficacy+Of+Subcutaneous+Or+Intravenous+Pf-06741086+In+Subjects+With+Severe+Hemophilia</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2017</study_first_submitted>
  <study_first_submitted_qc>November 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2017</study_first_posted>
  <last_update_submitted>May 24, 2018</last_update_submitted>
  <last_update_submitted_qc>May 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemophilia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemophilia A</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/data_requests</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

